Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(1)
•••
Post by skyhigh123on Apr 16, 2018 5:59am
165 Views
Post# 27889175

off topic other FDA CMC problems

off topic other FDA CMC problems

Prometic is not alone when it comes to FDA CMC issues

3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News

Summary

  • Progenics has a set back with the FDA.
  • AbbVie has a little less confidence in its lung cancer drug.
  • PharmaMar finishes a big stumble in myeloma.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Progenics has a set back with the FDA

Company: Progenics Pharmaceuticals (PGNX)

Therapy: Iobenguane I-131

Disease: Pheochromocytoma

News: PGNX announced that the FDAhas delayed the PDUFA date for its lead agent Azedra by three months, placing the action date on July 30. This was due to additional CMC information that the company needed to produce, which will take additional time to review. PGNX guided that the delay is not due to any issues relating to safety or efficacy


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities